The effect of comorbidities on COPD assessment: A pilot study

International Journal of COPD

Volumn 10, Issue , 2015, Pages 429-438

  Weinreic, Ulla Møller ^a   Thomsen, Lars Pilegaard ^b   Bielaska, Barbara ^c   Jensen, Vania Helbo ^a,d   Vuust, Morten ^c   Rees, Stephen Edward ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c NORTH DENMARK REGIONAL HOSPITAL   (Denmark)

^d HORSENS REGIONAL HOSPITAL   (Denmark)

Author keywords

Diffusing capacity of the lung for carbon monoxide; GOLD; High resolution computerized tomography; Inspiratory capacity; MMRC; Total lung capacity

Indexed keywords

CARBON MONOXIDE;

ADULT; AGED; ARTICLE; BODY PLETHYSMOGRAPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INSPIRATORY CAPACITY; LUNG CANCER; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PILOT STUDY; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; SPIROMETRY; TOTAL LUNG CAPACITY; CLUSTER ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DENMARK; DISEASE COURSE; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; VITAL CAPACITY;

AGED; CLUSTER ANALYSIS; COMORBIDITY; DENMARK; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INSPIRATORY CAPACITY; LUNG; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84923380303     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S76124     Document Type: Article

References (46)

1. Global Initiative for Chronic Obstructive Lung Disease. 2007 Update: Global Strategy for Diagnosis, Management, and Prevention of COPD. Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport07_0108.pdf. Accessed December 12, 2014.
2. García-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: A cross sectional study. BMC Fam Pract. 2013;14:11.
3. Divo M, Cote C, de Torres JP, et al; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161.
4. De Torres JP, Casanova C, Marín JM, et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax. 2014;69(9):799–804.
5. Koskela J, Kilpeläinen M, Kupiainen H, et al. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm Med. 2014;14:102.
6. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009;122(4):348–355.
7. Jones P, Miravitlles M, van der Molen T, Kulich K. Beyond FEV1 in COPD: A review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis. 2012;7:697–709.
8. Fan L, Xia Y, Guan Y, Zhang TF, Liu SY. Characteristic features of pulmonary function test, CT volume analysis and MR perfusion imaging in COPD patients with different HRCT phenotypes. Clin Respir J. 2014;8(1):45–54.
9. Global Initiative for Chonic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease: Updated 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed December 12, 2014.
10. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586.
11. Agusti A, Edwards LD, Celli B, et al; ECLIPSE Investigators. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–646.
12. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: A study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–981.
13. Soriano JB, Alfageme I, Almagro P, et al. Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest. 2013;143(3):694–702.
14. Bolinde M, Tsiachristas A, Kruis A, Chavannes N, Rutten-van Mölken M. Relating the new COPD GOLD strategy to quality-of-life and costs in a primary care population. Eur Respir Soc. 2013;42(Suppl 57):P267.
15. Boulet LP, Turcotte H, Hudon C, Carrier G, Maltais F. Clinical, physiological and radiological features of asthma with incomplete reversibility of airflow obstruction compared with those of COPD. Can Respir J. 1998;5(4):270–277.
16. Choi SH, Lee CH. Yearly progression of low lung attenuation area in low dose CT scan for asymptomatic current smokers with normal lung function or GOLD stage 1 COPD. Am J Respir Crit Care Med. 2014;189(D43):A5954.
17. Smith BM, Austin JH, Newell JD Jr, et al. Pulmonary emphysema subtypes on computed tomography: the MESA COPD study. Am J Med. 2014;127(1):947–1023.
18. Newell JD Jr. CT of emphysema. Radiol Clin North Am. 2002;40(1):31–42, vii.
19. COPDGene CT Workshop Group; Barr RG, Berkowitz EA, Bigazzi F, et al. A combined pulmonary-radiology workshop for visual evaluation of COPD: Study design, chest CT findings and concordance with quantitative evaluation. COPD. 2012;9(2):151–159.
20. Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med. 2010;181(4):353–359.
21. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(6):1395–1399.
22. Nishimura K, Yasui M, Nishimura T, Oga T. Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD? Respir Res. 2011;12:135.
23. Mahut B, Chevalier-Bidaud B, Plantier L, et al. Diffusing capacity for carbon monoxide is linked to ventilatory demand in patients with chronic obstructive pulmonary disease. COPD. 2012;9(1):16–21.
24. Farkhooy A, Janson C, Arnardóttir RH, Emtner M, Hedenström H, Malinovschi A. Impaired Carbon Monoxide Diffusing Capacity is the strongest lung function predictor of decline in 12 minute-walking distance in COPD; a 5-year follow-up study. COPD. Epub 2014 Sep 10.
25. Prignot J. Quantification and chemical markers of tobacco-exposure. Eur J Respir Dis. 1987;70(1):1–7.
26. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586.
27. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522.
28. Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. Eur Respir J. 1995;8(3):492–506.
29. MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–735.
30. Aziz ZA, Wells AU, Desai SR, et al. Functional impairment in emphysema: contribution of airway abnormalities and distribution of parenchymal disease. AJR Am J Roentgenol. 2005;185(6):1509–1515.
31. Barker AF. Bronchiectasis. N Engl J Med. 2002;346(18):1383–1393.
32. Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. 3rd ed. Mahwah, NJ: Lawrence Erlbaum Associates, Inc; 2003.
33. Stanford M. Chapter 7 Hierarchical cluster analysis. In: Statistics in Medicine. Vol 2. 3rd ed. London, UK: Elsevier, Inc; 2012:1–11.
34. Díez-Manglano J, Barquero-Romero J, Almagro P, et al; Working Group on COPD; Spanish Society of Internal Medicine. COPD patients with and without metabolic syndrome: Clinical and functional differences. Intern Emerg Med. 2014;9(4):419–425.
35. Güder G, Brenner S, Angermann CE, et al. “GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study”. Respir Res. 2012;13(1):13.
36. Miyazaki M, Nakamura H, Chubachi S, et al; Keio COPD Comorbidity Research (K-CCR) Group. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res. 2014;15:13.
37. Bland M. An Introduction to Medical Statistics. New York, NY: Oxford University Press Inc.; 2000.
38. Li LS, Caughey GE, Johnston KN. The association between co-morbidities and physical performance in people with chronic obstructive pulmonary disease: A systematic review. Chron Respir Dis. 2014;11(1):3–13.
39. D’Anna SE, Asnaghi R, Caramori G, et al. High-resolution computed tomography quantitation of emphysema is correlated with selected lung function values in stable COPD. Respiration. 2012;83(5):383–390.
40. Boshetto P, Miniati M, Miotto D, et al. Predominant emphysema phenotype in chronic obstructive pulmonary disease patients. Eur Respir J. 2003;21(3):450–454.
41. Garfield JL, Marchetti N, Gaughan JP, Steiner RM, Criner GJ. Total lung capacity by plethysmography and high-resolution computed tomography in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:119–126.
42. Celli BR, Decramer M, Lystig T, Kesten S, Tashkin DP. Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respir Res. 2012;13:66.
43. Bhatt SP, Sieren JC, Dransfield MT, et al; COPD Gene Investigators. Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction. Thorax. 2014;69(5):409–414.
44. Wille MM, Thomsen LH, Dirksen A, Petersen J, Pedersen JH, Shaker SB. Emphysema progression is visually detectable in low-dose CT in continuous but not in former smokers. Eur Radiol. 2014;24(11):2692–2699.
45. Sundaram B, Gross BH, Martinez FJ, et al. Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: Effect of predominance and distribution of findings. AJR Am J Roentgenol. 2008;191(4):1032–1039.
46. Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in COPD: Implications for the GOLD 2011 classification. Eur Respir J. 2013;42(3):647–654.